Use

Measurement of fibroblast growth factor‑23 (FGF‑23), a major regulator of phosphate homeostasis primarily produced in bone, provides critical diagnostic and management information in disorders of phosphate and bone metabolism. Elevated intact FGF‑23 levels decrease renal phosphate reabsorption and 1,25‑dihydroxyvitamin D formation, contributing to hypophosphatemia and osteomalacia despite normal renal function. This assay aids in evaluating hypophosphatemic and hyperphosphatemic conditions and elucidating bone–phosphate regulatory pathways.